Table 4.
Response to IPVD Therapy in Survivors Versus non-Survivors.
| Survivors (n = 33) | Non-survivors (n = 26) | p-value | |
|---|---|---|---|
| Days from admission to IPVD | 6 (2-9) | 6 (3-9) | 0.742 |
| PF ratio at commencing therapy (kPa) | 11.39 (9.90-12.92) | 11.28 (9.74-12.71) | 1.000 |
| Therapy received (n (%)) | |||
| Iloprost | 8 (24.2%) | 3 (11.5%) | 0.405 |
| NO | 4 (12.1%) | 5 (19.2%) | |
| NO and Iloprost | 21 (63.6%) | 18 (69.2%) | |
| NIV or MV at initiation of IPVD (n (%)) | |||
| NIV | 5 (15.2%) | 3 (11.5%) | 1.000 |
| MV | 28 (84.8%) | 23 (88.5%) | |
| Percentage change PaO2/FiO2 (%) | |||
| + 2 hours | 14.2 (-5.4-40.6) | -2.3 (-17.3-20.5) | 0.022* |
| + 6 hours | 20.0 (3.0-54.4) | 9.6 (-2.9-25.2) | 0.106 |
| + 12 hours | 31.6 (-0.4-80.4) | 18.1 (-7.2-46.7) | 0.174 |
| + 24 hours | 34.0 (3.3-60.4) | 17.6 (-7.1-44.7) | 0.045* |
| + 48 hours | 59.5 (9.7-108.1) | 6.5 (12.4-27.4) | <0.001* |
| + 72 hours | 70.8 (35.2-95.5) | -4.1 (-19.9-21.3) | <0.001* |
| A-a gradient at commencing therapy (kPa) | 54.3 (48.6-67.0) | 58.9 (50.0-70.3) | 0.376 |
| Percentage reduction A-a gradient (kPa) (%) | |||
| + 2 hours | 4.9 (-7.8-15.5) | 1.8 (-7.8-7.0) | 0.418 |
| + 6 hours | 19.7 (1.8-35.2) | 7.3 (-2.9-23.6) | 0.109 |
| + 12 hours | 26.4 (3.3-40.9) | 21.1 (2.4-32.7) | 0.246 |
| + 24 hours | 23.8 (2.5-48.7) | 21.3 (4.4-29.3) | 0.200 |
| + 48 hours | 38.4 (16.1-62.6) | 11.7 (-5.3-25.8) | <0.001* |
| + 72 hours | 44.7 (28.4-58.0) | 14.8 (-7.6-31.1) | <0.001* |